asciminib,imatinib,nilotinib
inhibikase
['cml', 'imatinib', 'nilotinib', 'asciminib', 'leukemia', 'myeloid']
asc4more (asciminib add-on to imatinib continued imatinib, or switch to nilotinib in patients with cml within 1 year) study presented by at #ash22 session this morning. pleased to contribute to the sc of this study #patientsinvolved 
Patient activist and research patient advocate. Life is precious.